These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1346838)

  • 1. Ondansetron in intractable nausea and vomiting.
    Nicholson S; Evans C; Mansi J
    Lancet; 1992 Feb; 339(8791):490. PubMed ID: 1346838
    [No Abstract]   [Full Text] [Related]  

  • 2. Ondansetron: A new concept in the management of emesis. Proceedings from an investigators meeting. Seattle, Washington, September 1990.
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-78. PubMed ID: 1387244
    [No Abstract]   [Full Text] [Related]  

  • 3. The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
    Clin Oncol (R Coll Radiol); 1991 Jul; 3(4):241-2. PubMed ID: 1834162
    [No Abstract]   [Full Text] [Related]  

  • 4. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odansetron.
    Betcher DL; Burnham N
    J Pediatr Oncol Nurs; 1991 Oct; 8(4):183-5. PubMed ID: 1834086
    [No Abstract]   [Full Text] [Related]  

  • 6. Ondansetron: a new entity in emesis control.
    Graves T
    DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
    Burnette PK; Perkins J
    Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose and long-term use of ondansetron.
    Vohra S; Juricic J
    Ann Pharmacother; 1992 Jan; 26(1):128-9. PubMed ID: 1535002
    [No Abstract]   [Full Text] [Related]  

  • 9. The big "little problem".
    Kapur PA
    Anesth Analg; 1991 Sep; 73(3):243-5. PubMed ID: 1831014
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo.
    Larijani GE; Gratz I; Afshar M; Minassian S
    Anesth Analg; 1991 Sep; 73(3):246-9. PubMed ID: 1831015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP; Taggart JR; Bender CM
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy?
    Dundee JW; McMillan CM; Yang J; Wright PM
    Br J Clin Pharmacol; 1992 Feb; 33(2):200-1. PubMed ID: 1532323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron vs dexamethasone for chemotherapy-induced emesis.
    Lancet; 1991 Aug; 338(8765):478-9. PubMed ID: 1714531
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs.
    McMillan C; Dundee JW; Abram WP
    Br J Cancer; 1991 Nov; 64(5):971-2. PubMed ID: 1834156
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis.
    Amin K; Bastani B
    Perit Dial Int; 2002; 22(4):539-40. PubMed ID: 12322834
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
    Early TE; Charbonneau J; McKnight G; Jenkins P
    J Post Anesth Nurs; 1995 Dec; 10(6):320-3. PubMed ID: 8632370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
    Pitts SR
    Ann Intern Med; 2014 Dec; 161(12):JC3. PubMed ID: 25506875
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
    Cole RM; Robinson F; Harvey L; Trethowan K; Murdoch V
    J Pain Symptom Manage; 1994 Jan; 9(1):48-50. PubMed ID: 7513334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
    Marschner NW; Adler M; Jaenicke F; Albrecht U; Nagel GA
    Onkologie; 1990 Aug; 13(4):313-5. PubMed ID: 2146577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.